Neutrophil-to-eosinophil ratio predicts the efficacy of avelumab in patients with advanced Urothelial Carcinoma enrolled in the MALVA study (Meet-URO 25).

Background Neutrophil-to-eosinophil ratio (NER) has been described to be associated with outcomes to immune checkpoint inhibitors (ICI) in several tumor types, but less is known about its role of in the response to avelumab in advanced urothelial cancer (aUC). Thus, we reported outcomes by NER of aUC patients treated with avelumab as maintenance after initial response to platinum-based chemotherapy (CT) and enrolled in the MALVA study (Maintenance with AVeLumAb in advanced urothelial neoplasms in response to first-line chemotherapy: an observational retrospective study-Meet-URO 25). Patients and Methods Median NER (mNER) at baseline and after 3 cycles of avelumab were calculated. Progression-free survival (PFS), overall survival (OS) by NER were reported. Results At the cutoff date (April 15, 2023), a total of 109 patients were included. The mNER was 28.05 at baseline and 24.46 after 3 cycles of avelumab, respectively. Median PFS was not reached (NR) for patients with baseline NER less than the median (更多